Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.73
+0.15 (1.19%)
Mar 9, 2026, 3:33 PM EDT - Market open

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
458369612503424534
Upgrade
Market Cap Growth
-0.97%-39.78%21.70%18.72%-20.71%-
Upgrade
Enterprise Value
21794224219236610
Upgrade
Last Close Price
12.5810.2817.2915.0913.5217.12
Upgrade
PE Ratio
--9.33---
Upgrade
PS Ratio
18.1514.502.903.90--
Upgrade
PB Ratio
1.481.201.432.081.991.79
Upgrade
P/TBV Ratio
1.511.201.432.081.991.79
Upgrade
P/FCF Ratio
---3.75--
Upgrade
P/OCF Ratio
---3.60--
Upgrade
EV/Sales Ratio
8.523.711.061.69--
Upgrade
EV/EBITDA Ratio
--4.41---
Upgrade
EV/EBIT Ratio
--4.77---
Upgrade
EV/FCF Ratio
---1.63--
Upgrade
Debt / Equity Ratio
0.170.170.140.280.12-
Upgrade
Debt / EBITDA Ratio
--0.924.68--
Upgrade
Debt / FCF Ratio
---0.51--
Upgrade
Net Debt / Equity Ratio
-0.80-0.80-0.84-1.17-0.77-0.97
Upgrade
Net Debt / EBITDA Ratio
1.611.61-7.10883.921.715.82
Upgrade
Net Debt / FCF Ratio
1.891.898.07-2.111.685.25
Upgrade
Asset Turnover
0.060.060.420.36--
Upgrade
Quick Ratio
12.2012.2010.782.268.6243.32
Upgrade
Current Ratio
12.5312.5311.152.339.5544.46
Upgrade
Return on Equity (ROE)
-39.13%-39.13%19.56%-2.94%-37.01%-30.19%
Upgrade
Return on Assets (ROA)
-21.58%-21.58%5.90%-0.55%-21.79%-18.29%
Upgrade
Return on Invested Capital (ROIC)
-244.42%-241.38%350.11%41.75%-233.30%-1165.02%
Upgrade
Return on Capital Employed (ROCE)
-44.20%-44.20%9.70%-1.00%-42.30%-17.10%
Upgrade
Earnings Yield
-31.16%-38.99%10.72%-1.33%-22.33%-9.57%
Upgrade
FCF Yield
-28.08%-35.14%-7.30%26.68%-22.82%-10.38%
Upgrade
Buyback Yield / Dilution
-6.07%-6.07%-18.01%-5.62%-399.27%-467.09%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.